CRBP Corbus Pharmaceuticals Holdings Inc

Price (delayed)

$8

Market cap

$148.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.74

Enterprise value

$123.38M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 2

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is ...

Highlights
CRBP's debt has dropped by 58% year-on-year and by 26% since the previous quarter
Corbus Pharmaceuticals Holdings's EPS has decreased by 37% YoY but it has increased by 2.7% QoQ
Corbus Pharmaceuticals Holdings's net income has plunged by 68% YoY and by 8% from the previous quarter
The quick ratio fell by 34% YoY and by 3.5% QoQ

Key stats

What are the main financial stats of CRBP

CRBP stock price

How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
8.4%
1 week
4.71%
1 month
-23.95%
1 year
-5.55%
YTD
-1.72%
QTD
-14.8%

Financial performance

How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$89.84M
Net income
-$84.53M
Gross margin
N/A
Net margin
N/A
Corbus Pharmaceuticals Holdings's net income has plunged by 68% YoY and by 8% from the previous quarter
The operating income has dropped by 53% year-on-year and by 5% since the previous quarter

Price vs fundamentals

How does CRBP's price correlate with its fundamentals

Growth

What is Corbus Pharmaceuticals Holdings's growth rate over time

Valuation

What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
1.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has decreased by 37% YoY but it has increased by 2.7% QoQ
CRBP's P/B is 84% below its 5-year quarterly average of 6.6 and 13% below its last 4 quarters average of 1.2
The company's equity fell by 14% QoQ

Efficiency

How efficient is Corbus Pharmaceuticals Holdings business performance
CRBP's return on invested capital has dropped by 123% year-on-year and by 10% since the previous quarter
The ROE has shrunk by 92% YoY and by 8% QoQ
The ROA has plunged by 88% YoY and by 7% from the previous quarter

Dividends

What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBP.

Financial health

How did Corbus Pharmaceuticals Holdings financials performed over time
CRBP's total liabilities is up by 41% YoY but it is down by 12% from the previous quarter
The quick ratio fell by 34% YoY and by 3.5% QoQ
CRBP's debt is 99% smaller than its equity
CRBP's debt has dropped by 58% year-on-year and by 26% since the previous quarter
CRBP's debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.